Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | PTPRA | P18433 | 1/20 | 0.36 |
| ▸ | PTPRB | P23467 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8145540 | 1.00 | TSHR (0.62) | TSHRSMN1; SMN2CYP2D6POLBTDP1 | |
| SCHEMBL996850 | 0.98 | TSHR (0.65) | TSHRSMN1; SMN2CYP2D6POLBTDP1 | |
| SCHEMBL718256 | 0.98 | TSHR (0.65) | TSHRSMN1; SMN2CYP2D6POLBTDP1 | |
| Water SCHEMBL570669 | 0.96 | TSHR (0.62) | TSHRSMN1; SMN2CYP2D6POLBTDP1 | |
| Water SCHEMBL30394765 | 0.96 | TSHR (0.62) | TSHRSMN1; SMN2CYP2D6POLBTDP1 | |
| Potassium SCHEMBL1450612 | 0.96 | TSHR (0.62) | TSHRSMN1; SMN2CYP2D6POLBTDP1 | |
| SCHEMBL6568428 | 0.96 | TSHR (0.62) | TSHRSMN1; SMN2CYP2D6POLBTDP1 | |
| SCHEMBL301148 | 0.96 | TSHR (0.62) | TSHRSMN1; SMN2CYP2D6POLBTDP1 | |
| SCHEMBL6569261 | 0.96 | TSHR (0.62) | TSHRSMN1; SMN2CYP2D6POLBTDP1 | |
| Water SCHEMBL1536886 | 0.94 | TSHR (0.60) | TSHRSMN1; SMN2CYP2D6POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5149868-A | Carbonylation process | SHELL OIL COMPANY (US) | 1992-09-22 | — | — | US | claimed |
| US-20240216521-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | IMMUNOGEN INC (US) | 2024-07-04 | — | — | US | disclosed |
| US-11833214-B2 | Methods of preparing cell-binding agent-drug conjugates | IMMUNOGEN, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| CN-110359097-B | Method for obtaining On-DNA aromatic hydrocarbon compound through Suzuki coupling reaction in construction of DNA coding compound library | 上海药明康德新药开发有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-110331447-B | Method for preparing On-DNA aryl alkyne compound in construction of DNA coding compound library | 上海药明康德新药开发有限公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3941527-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | ImmunoGen, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20200405874-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | IMMUNOGEN, INC. | 2020-12-31 | — | — | US | disclosed |
| WO-2020191306-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | IMMUNOGEN, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| EP-0489472-B1 | Carbonylation process and catalyst composition | SHELL INT RESEARCH (NL) | 1997-10-29 | — | — | EP | disclosed |
| US-5149868-A | Carbonylation process | SHELL OIL COMPANY (US) | 1992-09-22 | — | — | US | disclosed |
| EP-0489472-A2 | Carbonylation process and catalyst composition | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1992-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833214-B2 | Methods of preparing cell-binding agent-drug conjugates | EPCAM, CD2BP2, XPA | TSHR 2222/4885SMN1; SMN2 3191/4885CYP2D6 2255/4885 |
| US-20200405874-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | EPCAM, CD2BP2, XPA | TSHR 2222/4885SMN1; SMN2 3191/4885CYP2D6 2255/4885 |
| US-20240216521-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | EPCAM, CD2BP2, XPA | TSHR 2222/4885SMN1; SMN2 3191/4885CYP2D6 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.